Lumito’s founder and Board member Stefan Andersson-Engels presented at the prestigious Gordon Research Conference 2026
Lumito AB (publ) ("Lumito" or the "Company") announces today tha Company’s founder and Board member Stefan Andersson-Engels has participated as an invited speaker at the prestigious conference Optics and Photonics in Medicine and Biology Gordon Research Conference (GRC) 2026. During the conference, Stefan Andersson-Engels presented the lecture "Illuminating Biology Across Scales: Upconverting Nanoparticles as Background-Free […]
Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform
Lumito AB (publ) ("Lumito" or the "Company") and Offspring Biosciences Sweden AB ("Offspring Biosciences") today announce promising initial results from the pilot study evaluating Lumito's proprietary tissue labelling and high-sensitivity imaging platform in combination with Offspring Biosciences' automated Immunohistochemistry (IHC) platform. Offspring Biosciences has transferred Lumito's SCIZYS Erbium manual assay on to the Dx Ultra […]
Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology
Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company has initiated a pilot project together with the Swedish biotech company Navinci Diagnostics AB (”Navinci”) to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis. The pilot project aims to combine Lumito’s high-sensitivity image analysis platform with Navinci’s in […]
Lumito appoints Pascal Bamford as new Chair of the Scientific Advisory Board
Lumito AB (publ) ("Lumito" or the "Company") today announces that Pascal Bamford has been appointed Chair of the Company’s Scientific Advisory Board (SAB). He succeeds Paul Waring, who will continue to serve as a trusted advisor and remain closely engaged with Lumito going forward. The change reflects Lumito’s transition into an increasingly commercial phase, where […]
Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm
Lumito AB (publ) ("Lumito" or the "Company") today announces that two scientific abstracts have been accepted for poster presentation at the European Congress of Pathology 2026, taking place at Stockholmsmässan, Stockholm, Sweden, on September 12-16, 2026. The Company will also participate as an exhibitor at the congress, which is one of the largest international meetings […]
Lumito strengthens Scientific Advisory Board with internationally leading experts in life science and drug development
Lumito AB (publ) ("Lumito" or the "Company") today announces the appointment of two internationally recognised experts to its Scientific Advisory Board (SAB): Professor Arutha Kulasinghe, one of the world's leading researchers in spatial biology, and Gemma Jones, Translational Pathology Scientific Director at AstraZeneca and with expertise in biomarker-driven drug development. These appointments give Lumito stronger […]
Lumito awarded Vinnova funding to strengthen regulatory and quality capabilities during commercialisation
Lumito AB (“Lumito” or the “Company”) today announces that it has been awarded funding of up to SEK 200,000 from Vinnova under the “Medtech4Health: Competence Enhancement in SMEs, Spring 2026” programme. The project will run from May to December 2026 and is intended to strengthen the Company’s regulatory competence, with a particular focus on quality […]
Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026
Lumito AB (publ) (“Lumito” or the “Company”) issued warrants of series TO7 in connection with a rights issue during the fourth quarter of 2025. Five hundred (500) warrants entitle the holder to subscribe for one (1) new share in the Company. The subscription price for the warrants of series TO7 was set at 70 percent […]
Lumito AB publishes Interim Report Q1 2026
Financial overviewFirst quarter 2026, 1 January – 31 MarchNet sales amounted to 78 (0) KSEK.Result after taxes amounted to -10,495 (-11,803) KSEK.Earnings per share before and after dilution amounted to -3.05 (-0.04) SEK.Cash flow from operating activities amounted to -6,732 (-6,784) KSEK.Cash and cash equivalents at the balance sheet date amounted to 8,990 (14,711) KSEK. […]
Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026
Lumito AB (publ) (“Lumito” or the “Company”) will publish its Q1 report for 2026 on 7 May 2026. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:30 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction to Lumito and […]